Barinthus Biotherapeutics (BRNS) Other Accumulated Expenses (2020 - 2023)

Barinthus Biotherapeutics has reported Other Accumulated Expenses for 4 years, with the latest figure at $1.3 million in Q3 2023.

• For the quarter ending Q3 2023, Other Accumulated Expenses fell 50.17% year-over-year to $1.3 million; the trailing twelve-month figure through Sep 2023 stood at $1.3 million (down 50.17% YoY), and the FY2022 full-year result was $932000.0, down 25.56% from the prior year.
• Other Accumulated Expenses for Q3 2023 stood at $1.3 million, up from $638000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $2.6 million in Q3 2022, with the low at $46000.0 in Q2 2021.
• Historically, Other Accumulated Expenses has averaged $922818.2 across 4 years, with a median of $932000.0 in 2022.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses soared 2091.3% — and 2023, when it sank 50.17%.
• Barinthus Biotherapeutics' Other Accumulated Expenses stood at $266000.0 in 2020, then jumped by 370.68% to $1.3 million in 2021, then dropped by 25.56% to $932000.0 in 2022, then jumped by 41.09% to $1.3 million in 2023.
• The last three Other Accumulated Expenses figures came in at $1.3 million (Q3 2023), $638000.0 (Q2 2023), and $932000.0 (Q4 2022), per Business Quant data.